MX2021005611A - Control de metales traza durante la produccion de anticuerpos anti-cd38. - Google Patents
Control de metales traza durante la produccion de anticuerpos anti-cd38.Info
- Publication number
- MX2021005611A MX2021005611A MX2021005611A MX2021005611A MX2021005611A MX 2021005611 A MX2021005611 A MX 2021005611A MX 2021005611 A MX2021005611 A MX 2021005611A MX 2021005611 A MX2021005611 A MX 2021005611A MX 2021005611 A MX2021005611 A MX 2021005611A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- during production
- control
- trace metals
- metals during
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
- C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La descripción se relaciona con métodos para controlar metales traza durante la producción de anticuerpos anti-CD38, sustancias farmacológicas y productos farmacológicos generados usando los métodos, y usos de las sustancias farmacológicas y productos farmacológicos generados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862760782P | 2018-11-13 | 2018-11-13 | |
PCT/IB2019/059766 WO2020100073A1 (en) | 2018-11-13 | 2019-11-13 | Control of trace metals during production of anti-cd38 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021005611A true MX2021005611A (es) | 2021-06-30 |
Family
ID=70551717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021005611A MX2021005611A (es) | 2018-11-13 | 2019-11-13 | Control de metales traza durante la produccion de anticuerpos anti-cd38. |
Country Status (14)
Country | Link |
---|---|
US (1) | US11634499B2 (es) |
EP (1) | EP3880824B1 (es) |
JP (2) | JP2022513018A (es) |
KR (1) | KR20210091763A (es) |
CN (1) | CN113015805A (es) |
AU (1) | AU2019379858B2 (es) |
CA (1) | CA3117447C (es) |
EA (1) | EA202191352A1 (es) |
IL (1) | IL282970A (es) |
MA (1) | MA54248A (es) |
MX (1) | MX2021005611A (es) |
SG (1) | SG11202104092UA (es) |
TW (1) | TW202039849A (es) |
WO (1) | WO2020100073A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
EP4219561A3 (en) | 2015-05-20 | 2023-11-08 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies |
MA43187B1 (fr) * | 2015-11-03 | 2021-02-26 | Janssen Biotech Inc | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations |
CN113015805A (zh) | 2018-11-13 | 2021-06-22 | 詹森生物科技公司 | 抗cd38抗体产生期间的痕量金属的控制 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4072565A (en) | 1974-11-04 | 1978-02-07 | The Dow Chemical Company | Production of viruses in tissue culture without use of serum |
EP0082974B1 (en) | 1981-12-24 | 1986-05-14 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for the cultivation of normal diploid cells and cultivation medium used therefor |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
FR2543158B1 (fr) | 1983-03-24 | 1985-11-15 | Inst Nat Sante Rech Med | Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu |
ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
US6656466B1 (en) | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
JP4306813B2 (ja) | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
US5804420A (en) | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
US6924124B1 (en) | 2002-08-23 | 2005-08-02 | Immunex Corporation | Feeding strategies for cell culture |
CN1942588B (zh) | 2003-03-05 | 2013-06-12 | 海洋酶公司 | 可溶性透明质酸酶糖蛋白(sHASEGP)、制备它们的方法、它们的用途和包含它们的药物组合物 |
ES2344789T5 (es) | 2003-05-15 | 2017-06-14 | Wyeth Llc | Alimentación restringida de glucosa para el cultivo de células animales |
TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
BRPI0618399B1 (pt) | 2005-10-12 | 2023-10-03 | Morphosys Ag | Anticorpo específico anti-cd38 humano, composição de ácido nucleico, vetor de expressão, composição farmacêutica, uso do anticorpo e uso de uma composição farmacêutica |
KR101423344B1 (ko) | 2006-01-04 | 2014-07-30 | 백스터 인터내셔널 인코포레이티드 | 올리고펩티드-무함유 세포 배양 배지를 이용하여 단백질을 발현시키는 방법 |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
US20090076249A1 (en) * | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
CN101970730A (zh) | 2007-12-19 | 2011-02-09 | 森托科尔奥索生物科技公司 | 通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法 |
US9062106B2 (en) * | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
CN105392878A (zh) * | 2013-07-23 | 2016-03-09 | 百康有限公司 | 用于控制蛋白质中的岩藻糖基化水平的方法 |
US20150139988A1 (en) * | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
BR112016017660B1 (pt) * | 2014-02-27 | 2022-04-19 | F. Hoffmann-La Roche Ag | Método para a produção de uma glicoproteína recombinante |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
KR101660580B1 (ko) * | 2014-04-02 | 2016-09-28 | 프레스티지 바이오파마 피티이. 엘티디. | 항체의 당 함량 조절을 통한 항체의 제조 방법 |
US10844416B2 (en) * | 2015-06-01 | 2020-11-24 | Biogen Ma Inc. | Manganese supplementation for control of glycosylation in mammalian cell culture process |
CN113015805A (zh) | 2018-11-13 | 2021-06-22 | 詹森生物科技公司 | 抗cd38抗体产生期间的痕量金属的控制 |
-
2019
- 2019-11-13 CN CN201980074932.1A patent/CN113015805A/zh active Pending
- 2019-11-13 AU AU2019379858A patent/AU2019379858B2/en active Active
- 2019-11-13 JP JP2021525797A patent/JP2022513018A/ja active Pending
- 2019-11-13 TW TW108141240A patent/TW202039849A/zh unknown
- 2019-11-13 MA MA054248A patent/MA54248A/fr unknown
- 2019-11-13 CA CA3117447A patent/CA3117447C/en active Active
- 2019-11-13 SG SG11202104092UA patent/SG11202104092UA/en unknown
- 2019-11-13 EA EA202191352A patent/EA202191352A1/ru unknown
- 2019-11-13 WO PCT/IB2019/059766 patent/WO2020100073A1/en unknown
- 2019-11-13 EP EP19885702.1A patent/EP3880824B1/en active Active
- 2019-11-13 MX MX2021005611A patent/MX2021005611A/es unknown
- 2019-11-13 KR KR1020217017776A patent/KR20210091763A/ko active Search and Examination
- 2019-11-13 US US16/682,551 patent/US11634499B2/en active Active
-
2021
- 2021-05-05 IL IL282970A patent/IL282970A/en unknown
-
2024
- 2024-05-30 JP JP2024087951A patent/JP2024129019A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MA54248A (fr) | 2021-09-22 |
KR20210091763A (ko) | 2021-07-22 |
SG11202104092UA (en) | 2021-05-28 |
BR112021008879A2 (pt) | 2021-10-26 |
IL282970A (en) | 2021-06-30 |
EP3880824A4 (en) | 2022-08-10 |
US11634499B2 (en) | 2023-04-25 |
CA3117447C (en) | 2024-06-04 |
AU2019379858B2 (en) | 2024-01-04 |
WO2020100073A1 (en) | 2020-05-22 |
EP3880824B1 (en) | 2024-07-24 |
AU2019379858A1 (en) | 2021-05-20 |
CN113015805A (zh) | 2021-06-22 |
EA202191352A1 (ru) | 2021-08-11 |
JP2024129019A (ja) | 2024-09-26 |
JP2022513018A (ja) | 2022-02-07 |
US20200148782A1 (en) | 2020-05-14 |
TW202039849A (zh) | 2020-11-01 |
CA3117447A1 (en) | 2020-05-22 |
EP3880824A1 (en) | 2021-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021005611A (es) | Control de metales traza durante la produccion de anticuerpos anti-cd38. | |
PH12019502283A1 (en) | Anti-lag3 antibodies | |
PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
PH12017501365B1 (en) | Novel promoter and uses thereof | |
PH12017501042A1 (en) | Anti-cd38 antibodies for treatment of acute myeloid leukemia | |
MX2019002946A (es) | Anticuerpos anti-pd-1 y sus usos. | |
MX2024001394A (es) | Anticuerpos anti-bcma unicamente de cadena pesada. | |
MX2019011778A (es) | Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma. | |
MX2023006380A (es) | Anticuerpos anti-bcma unicamente de cadena pesada. | |
PH12019501357A1 (en) | Anti-ox40 antibodies and their uses | |
PH12020550529A1 (en) | Recombinant bacterium capable of producing l-lysine, construction method thereof and production method of l-lysine | |
MX2021014888A (es) | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda. | |
MX2019015563A (es) | Anticuerpos anti-bcma unicamente de cadena pesada. | |
PH12020500576A1 (en) | Method of treating cancers with antagonistic anti-pd-1 antibodies | |
TW201612319A (en) | Microorganism producing O-phosphoserine and a method for producing O-phosphoserine or L-cysteine using the same | |
MX2019011758A (es) | Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma. | |
EP3391965A4 (en) | RADICALLY DEVELOPING CATALYST, METHOD FOR PRODUCING A RADICAL, METHOD FOR PRODUCING AN OXIDATION REACTION PRODUCT, MEDICAMENTS AND MEDICAMENTS FOR AGRICULTURE AND LIVESTOCK | |
MX2017003301A (es) | Producto refractario, relleno para fabricar el producto, procedimiento para fabricar el producto y uso del producto refractario. | |
MX2019011730A (es) | Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma. | |
MX2020004093A (es) | Puzolana de vidrio activada. | |
MX2019009136A (es) | Aparato y proceso de flujo continuo para la produccion de derivado de acido boronico. | |
MX2018013334A (es) | Metodo para producir derivados de espirociclicos cis-alcoxi-sustituidos 1-h-pirrolidina-2,4-diona. | |
MY174840A (en) | Microorganism producing o-acetyl-homoserine, and method for producing o-acetyl-homoserine by using same | |
MX2017008776A (es) | Relleno para preparar un producto refractario, un procedimiento para preparar un producto refractario, un producto refractario, y uso de un producto refractario. | |
MX2017000519A (es) | Derivados de azaspiro(4.5)decano sustituido. |